Unknown PHASE4 INTERVENTIONAL 1-arm NCT03707847

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL)

Sponsor: Mingzhi Zhang

Conditions ALK-Positive Anaplastic Large Cell Lymphoma

Interventions Auto-HSCT Crizotinib Etoposide Capsule

Updated 5 times since 2018 Last updated: Oct 12, 2018 Started: Oct 1, 2018 Primary completion: Feb 1, 2020 Completion: Feb 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates ALK-Positive Anaplastic Large Cell Lymphoma and is currently ongoing. Mingzhi Zhang leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE4
Nov 2018 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mingzhi Zhang

Data source: Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China